<?xml version="1.0" encoding="utf-8"?>
<Label drug="Dutoprol" setid="23ab5537-5d5b-41d6-618c-974930319a48">
<Text><Section name="Boxed Warning section" id="34066-1">
Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered DUTOPROL, particularly in patients with ischemic heart disease, gradually reduce the dosage over a period of 1–2 weeks and monitor the patient. If angina markedly worsens or acute coronary ischemia develops, promptly reinstate DUTOPROL, and take measures appropriate for the management of unstable angina. Warn patients not to interrupt therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, avoid abruptly discontinuing DUTOPROL in patients treated only for hypertension.</Section>
<Section name="CONTRAINDICATIONS SECTION" id="34070-3">
Metoprolol succinate extended release/hydrochlorothiazide is contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs.</Section>
<Section name="DOSAGE &amp;amp; ADMINISTRATION SECTION" id="34068-7">
Dosing must be individualized considering baseline and target blood pressure as well as experience with individual agents. The side effects (see WARNINGS) of metoprolol succinate extended release are a mixture of dose-dependent phenomena (primarily bradycardia and fatigue); those of hydrochlorothiazide are a mixture of dose-dependent (primarily hypokalemia) and dose independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of metoprolol succinate extended release and hydrochlorothiazide will be associated with both sets of dose independent side effects. To minimize the known dose-related tolerability and safety-related effects of the individual agents, consideration should be given to initiating treatment at less than their maximum doses. DUTOPROL may be administered with other antihypertensive agents. DUTOPROL may be administered with or without food. DUTOPROL is administered once daily. Hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg once daily. Patients usually do not require doses in excess of 50 mg hydrochlorothiazide daily when used concomitantly with other antihypertensive agents. The usual initial dose of metoprolol succinate extended release is 25 to 100 mg daily in a single dose. Metoprolol succinate extended release doses greater than 400 mg have not been studied.        DUTOPROL may be substituted for treatment with individual components.          Use the dose necessary based on patient response once the need for combination product is established. Response rates are greater at higher doses. Patients with insufficient blood pressure effects with metoprolol succinate extended release or hydrochlorothiazide alone may be switched to DUTOPROL. The lowest DUTOPROL tablet available is 25/12.5 mg. A 50/6.25 mg dose can be achieved by splitting the 100/12.5 mg tablet. Subsequently titration may be carried out every 2 weeks up to a maximum of 200/25 mg (two DUTOPROL 100/12.5 mg tablets).          The usual regimens of therapy with DUTOPROL may be followed as long as the patient’s creatinine clearance is &amp;gt; 30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so DUTOPROL is not recommended.           The usual regimens of therapy with DUTOPROL may be followed in patients with mild hepatic impairment. In patients with moderate hepatic impairment, consideration should be given to initiation of DUTOPROL with lower doses of hydrochlorothiazide.</Section>
<Section name="DRUG INTERACTIONS SECTION" id="34073-7">
Catecholamine-depleting drugs (eg, reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with DUTOPROL plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.  Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration. In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate release metoprolol 200 mg tripled the concentration of S—metoprolol and doubled the metoprolol elimination half—life. In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate—release metoprolol 50 mg t.i.d. resulted in two— to five-fold increases in the steady-state concentration of metoprolol. These increases in plasma concentration would decrease the cardioselectivity of metoprolol. Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. Concomitant use with beta blockers can increase the risk of bradycardia.  If clonidine and a beta blocker, such as metoprolol are coadministered, withdraw the beta-blocker several days before the gradual withdrawal of clonidine because beta-blockers may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, delay the introduction of beta-blockers for several days after clonidine administration has stopped (see Warnings).          When administered concurrently the following drugs may interact with thiazide diuretics:  Alcohol, barbiturates, or narcotics – Potentiation of orthostatic hypotension may occur.  Antidiabetic drugs (oral agents and insulin) – Dosage adjustment of the antidiabetic drug may be required.  Other antihypertensive drugs – Additive effect or potentiation.  Cholestyramine and colestipol resins – Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.  Corticosteroids, ACTH – Intensified electrolyte depletion, particularly hypokalemia.  Pressor amines (eg, norepinephrine) – Possible decreased response to pressor amines but not sufficient to preclude their use.  Skeletal muscle relaxants, nondepolarizing (eg, tubocurarine) – Possible increased responsiveness to the muscle relaxant.  Lithium – Generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with DUTOPROL.  Non-steroidal Anti-inflammatory Drugs – In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing and thiazide diuretics. Therefore, when DUTOPROL and non-steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</Section>
<Section name="WARNINGS SECTION" id="34071-1">
Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered DUTOPROL, particularly in patients with ischemic heart disease, gradually reduce the dosage over a period of 1–2 weeks and monitor the patient. If angina markedly worsens or acute coronary ischemia develops, promptly reinstate DUTOPROL, and take measures appropriate for the management of unstable angina. Warn patients not to interrupt therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, avoid abruptly discontinuing DUTOPROL in patients treated only for hypertension.            Bronchospastic Disease: PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta1 cardio-selectivity, however, metoprolol succinate extended release/hydrochlorothiazide may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Because beta1-selectivity is not absolute, use the lowest possible dose of DUTOPROL. Bronchodilators, including beta2—agonists, should be readily available or administered concomitantly (see DOSAGE AND ADMINISTRATION).  Pheochromocytoma: If DUTOPROL is used in the setting of pheochromocytoma, it should be given in combination with an alpha blocker, and only after the alpha blocker has been initiated. Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.    Major Surgery: Avoid initiation of high-dose regimen of extended— release metoprolol in patients undergoing non-cardiac surgery, since such use in patients with cardiovascular risk factors has been associated with bradycardia, hypotension, stroke and death. Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery, however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.    Diabetes and Hypoglycemia: Beta-blockers may mask tachycardia occurring with hypoglycemia, but other manifestations such as dizziness and sweating may not be significantly affected. (See PRECAUTIONS, General, Hydrochlorothiazide).   Thyrotoxicosis: Beta-adrenergic blockade may mask certain clinical signs of hyperthyroidism, such as tachycardia. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta—blockade, which might precipitate a thyroid storm.   Peripheral Vascular Disease: Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.   Calcium Channel Blockers: Because of significant inotropic and chronotropic effects in patients treated with beta-blockers and calcium channel blockers of the verapamil and diltiazem type, caution should be exercised in patients treated with these agents concomitantly.</Section>
</Text><Sentences>
<Sentence id="5389" LabelDrug="Dutoprol" section="34066-1">
<SentenceText>Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred.</SentenceText>
</Sentence>
<Sentence id="5390" LabelDrug="Dutoprol" section="34066-1">
<SentenceText>When discontinuing chronically administered DUTOPROL, particularly in patients with ischemic heart disease, gradually reduce the dosage over a period of 1–2 weeks and monitor the patient.</SentenceText>
</Sentence>
<Sentence id="5391" LabelDrug="Dutoprol" section="34066-1">
<SentenceText>If angina markedly worsens or acute coronary ischemia develops, promptly reinstate DUTOPROL, and take measures appropriate for the management of unstable angina.</SentenceText>
</Sentence>
<Sentence id="5392" LabelDrug="Dutoprol" section="34066-1">
<SentenceText>Warn patients not to interrupt therapy without the physician’s advice.</SentenceText>
</Sentence>
<Sentence id="5393" LabelDrug="Dutoprol" section="34066-1">
<SentenceText>Because coronary artery disease is common and may be unrecognized, avoid abruptly discontinuing DUTOPROL in patients treated only for hypertension.</SentenceText>
</Sentence>
<Sentence id="5394" LabelDrug="Dutoprol" section="34070-3">
<SentenceText>Metoprolol succinate extended release/hydrochlorothiazide is contraindicated in patients in cardiogenic shock, overt cardiac failure , second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs.</SentenceText>
</Sentence>
<Sentence id="5395" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>Dosing must be individualized considering baseline and target blood pressure as well as experience with individual agents.</SentenceText>
</Sentence>
<Sentence id="5396" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>The side effects , the former much more common than the latter.</SentenceText>
</Sentence>
<Sentence id="5397" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>Therapy with any combination of metoprolol succinate extended release and hydrochlorothiazide will be associated with both sets of dose independent side effects.</SentenceText>
</Sentence>
<Sentence id="5398" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>To minimize the known dose-related tolerability and safety-related effects of the individual agents, consideration should be given to initiating treatment at less than their maximum doses.</SentenceText>
</Sentence>
<Sentence id="5399" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>DUTOPROL may be administered with other antihypertensive agents.</SentenceText>
</Sentence>
<Sentence id="5400" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>DUTOPROL may be administered with or without food.</SentenceText>
</Sentence>
<Sentence id="5401" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>Hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg once daily.</SentenceText>
</Sentence>
<Sentence id="5402" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>Patients usually do not require doses in excess of 50 mg hydrochlorothiazide daily when used concomitantly with other antihypertensive agents.</SentenceText>
</Sentence>
<Sentence id="5403" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>The usual initial dose of metoprolol succinate extended release is 25 to 100 mg daily in a single dose.</SentenceText>
</Sentence>
<Sentence id="5404" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>Metoprolol succinate extended release doses greater than 400 mg have not been studied.</SentenceText>
</Sentence>
<Sentence id="5405" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>DUTOPROL may be substituted for treatment with individual components.</SentenceText>
</Sentence>
<Sentence id="5406" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>Use the dose necessary based on patient response once the need for combination product is established.</SentenceText>
</Sentence>
<Sentence id="5407" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>Response rates are greater at higher doses.</SentenceText>
</Sentence>
<Sentence id="5408" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>Patients with insufficient blood pressure effects with metoprolol succinate extended release or hydrochlorothiazide alone may be switched to DUTOPROL.</SentenceText>
</Sentence>
<Sentence id="5409" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>The lowest DUTOPROL tablet available is 25/12.5 mg. A 50/6.25 mg dose can be achieved by splitting the 100/12.5 mg tablet.</SentenceText>
</Sentence>
<Sentence id="5410" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>Subsequently titration may be carried out every 2 weeks up to a maximum of 200/25 mg (two DUTOPROL 100/12.5 mg tablets).</SentenceText>
</Sentence>
<Sentence id="5411" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>The usual regimens of therapy with DUTOPROL may be followed as long as the patient’s creatinine clearance is &gt; 30 mL/min.</SentenceText>
</Sentence>
<Sentence id="5412" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so DUTOPROL is not recommended.</SentenceText>
</Sentence>
<Sentence id="5413" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>The usual regimens of therapy with DUTOPROL may be followed in patients with mild hepatic impairment.</SentenceText>
</Sentence>
<Sentence id="5414" LabelDrug="Dutoprol" section="34068-7">
<SentenceText>In patients with moderate hepatic impairment, consideration should be given to initiation of DUTOPROL with lower doses of hydrochlorothiazide.</SentenceText>
</Sentence>
<Sentence id="5415" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Catecholamine-depleting drugs (eg, reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents.</SentenceText>
<Mention id="M15" type="SpecificInteraction" span="94 15" str="additive effect" code="NO MAP"/>
<Mention id="M2" type="Precipitant" span="0 29" str="Catecholamine-depleting drugs" code="N0000175640"/>
<Mention id="M5" type="Precipitant" span="65 3;70 10" str="MAO | inhibitors" code="N0000175744"/>
<Mention id="M8" type="Precipitant" span="46 34" str="monoamine oxidase (MAO) inhibitors" code="N0000175744"/>
<Mention id="M11" type="Precipitant" span="46 17;70 10" str="monoamine oxidase | inhibitors" code="N0000175744"/>
<Mention id="M14" type="Precipitant" span="35 9" str="reserpine" code="8B1QWR724A"/>
<Interaction id="I1" type="Pharmacodynamic interaction" trigger="M15" precipitant="M2" effect="M15"/>
<Interaction id="I2" type="Pharmacodynamic interaction" trigger="M15" precipitant="M5" effect="M15"/>
<Interaction id="I3" type="Pharmacodynamic interaction" trigger="M15" precipitant="M8" effect="M15"/>
<Interaction id="I4" type="Pharmacodynamic interaction" trigger="M15" precipitant="M11" effect="M15"/>
<Interaction id="I5" type="Pharmacodynamic interaction" trigger="M15" precipitant="M14" effect="M15"/>
</Sentence>
<Sentence id="5416" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Observe patients treated with DUTOPROL plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.</SentenceText>
<Mention id="M28" type="Trigger" span="0 7;69 12" str="Observe | for evidence"/>
<Mention id="M29" type="Precipitant" span="46 22" str="catecholamine depletor" code="N0000175640"/>
<Mention id="M18" type="SpecificInteraction" span="138 7" str="vertigo" code="399153001: Vertigo (finding)"/>
<Mention id="M21" type="SpecificInteraction" span="85 11" str="hypotension" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M24" type="SpecificInteraction" span="159 20" str="postural hypotension" code="28651003: Orthostatic hypotension (disorder)"/>
<Mention id="M27" type="SpecificInteraction" span="100 18" str="marked bradycardia" code="48867003: Bradycardia (finding)"/>
<Mention id="M30" type="SpecificInteraction" span="147 7" str="syncope" code="271594007: Syncope (disorder)"/>
<Interaction id="I6" type="Pharmacodynamic interaction" trigger="M28" precipitant="M29" effect="M18"/>
<Interaction id="I7" type="Pharmacodynamic interaction" trigger="M28" precipitant="M29" effect="M21"/>
<Interaction id="I8" type="Pharmacodynamic interaction" trigger="M28" precipitant="M29" effect="M24"/>
<Interaction id="I9" type="Pharmacodynamic interaction" trigger="M28" precipitant="M29" effect="M27"/>
<Interaction id="I10" type="Pharmacodynamic interaction" trigger="M28" precipitant="M29" effect="M30"/>
</Sentence>
<Sentence id="5417" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration.</SentenceText>
<Mention id="M39" type="Trigger" span="99 8;119 13" str="increase | concentration"/>
<Mention id="M32" type="Precipitant" span="0 25" str="Drugs that inhibit CYP2D6" code="N0000182135"/>
<Mention id="M34" type="Precipitant" span="45 10" str="fluoxetine" code="01K63SUP8D"/>
<Mention id="M36" type="Precipitant" span="57 10" str="paroxetine" code="41VRH5220H"/>
<Mention id="M38" type="Precipitant" span="73 11" str="propafenone" code="68IQX3T69U"/>
<Mention id="M40" type="Precipitant" span="34 9" str="quinidine" code="ITX08688JL"/>
<Interaction id="I11" type="Pharmacokinetic interaction" trigger="M39" precipitant="M32" effect="C54355"/>
<Interaction id="I12" type="Pharmacokinetic interaction" trigger="M39" precipitant="M34" effect="C54355"/>
<Interaction id="I13" type="Pharmacokinetic interaction" trigger="M39" precipitant="M36" effect="C54355"/>
<Interaction id="I14" type="Pharmacokinetic interaction" trigger="M39" precipitant="M38" effect="C54355"/>
<Interaction id="I15" type="Pharmacokinetic interaction" trigger="M39" precipitant="M40" effect="C54355"/>
</Sentence>
<Sentence id="5418" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate release metoprolol 200 mg tripled the concentration of S—metoprolol and doubled the metoprolol elimination half—life.</SentenceText>
<Mention id="M41" type="Trigger" span="142 25" str="tripled the concentration"/>
<Mention id="M44" type="Precipitant" span="85 9" str="quinidine" code="ITX08688JL"/>
<Mention id="M43" type="Trigger" span="188 7;223 9" str="doubled | half—life"/>
<Interaction id="I16" type="Pharmacokinetic interaction" trigger="M41" precipitant="M44" effect="C54355"/>
<Interaction id="I17" type="Pharmacokinetic interaction" trigger="M43" precipitant="M44" effect="C54603"/>
</Sentence>
<Sentence id="5419" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate—release metoprolol 50 mg t.i.d. resulted in two— to five-fold increases in the steady-state concentration of metoprolol.</SentenceText>
<Mention id="M45" type="Trigger" span="169 43" str="increases in the steady-state concentration"/>
<Mention id="M46" type="Precipitant" span="66 11" str="propafenone" code="68IQX3T69U"/>
<Interaction id="I18" type="Pharmacokinetic interaction" trigger="M45" precipitant="M46" effect="C54355"/>
</Sentence>
<Sentence id="5420" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>These increases in plasma concentration would decrease the cardioselectivity of metoprolol.</SentenceText>
</Sentence>
<Sentence id="5421" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate.</SentenceText>
<Mention id="M75" type="Trigger" span="57 32" str="slow atrioventricular conduction "/>
<Mention id="M76" type="Trigger" span="94 19" str=" decrease heart rate"/>
<Mention id="M53" type="Precipitant" span="22 9" str="clonidine" code="MN3L5RMN02"/>
<Mention id="M74" type="SpecificInteraction" span="94 19" str="decrease heart rate" code="48867003: Bradycardia (finding)"/>
<Mention id="M78" type="SpecificInteraction" span="57 32" str="slow atrioventricular conduction" code="233917008: Atrioventricular block (disorder)"/>
<Mention id="M61" type="Precipitant" span="0 20" str="Digitalis glycosides" code="F1T8QT9U8B"/>
<Mention id="M69" type="Precipitant" span="33 9" str="diltiazem" code="EE92BBP03H"/>
<Mention id="M77" type="Precipitant" span="47 9" str="verapamil" code="CJ0O37KU29"/>
<Interaction id="I19" type="Pharmacodynamic interaction" trigger="M75;M76" precipitant="M53" effect="M74"/>
<Interaction id="I20" type="Pharmacodynamic interaction" trigger="M75;M76" precipitant="M53" effect="M78"/>
<Interaction id="I21" type="Pharmacodynamic interaction" trigger="M75;M76" precipitant="M61" effect="M78"/>
<Interaction id="I22" type="Pharmacodynamic interaction" trigger="M75;M76" precipitant="M61" effect="M74"/>
<Interaction id="I23" type="Pharmacodynamic interaction" trigger="M75;M76" precipitant="M69" effect="M74"/>
<Interaction id="I24" type="Pharmacodynamic interaction" trigger="M75;M76" precipitant="M69" effect="M78"/>
<Interaction id="I25" type="Pharmacodynamic interaction" trigger="M75;M76" precipitant="M77" effect="M74"/>
<Interaction id="I26" type="Pharmacodynamic interaction" trigger="M75;M76" precipitant="M77" effect="M78"/>
</Sentence>
<Sentence id="5422" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Concomitant use with beta blockers can increase the risk of bradycardia.</SentenceText>
</Sentence>
<Sentence id="5423" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>If clonidine and a beta blocker, such as metoprolol are coadministered, withdraw the beta-blocker several days before the gradual withdrawal of clonidine because beta-blockers may exacerbate the rebound hypertension that can follow the withdrawal of clonidine.</SentenceText>
<Mention id="M79" type="Trigger" span="180 10" str="exacerbate"/>
<Mention id="M80" type="Precipitant" span="3 9" str="clonidine" code="MN3L5RMN02"/>
<Mention id="M81" type="SpecificInteraction" span="195 20" str="rebound hypertension" code="84094009: Rebound hypertension (disorder)"/>
<Interaction id="I27" type="Pharmacodynamic interaction" trigger="M79" precipitant="M80" effect="M81"/>
</Sentence>
<Sentence id="5424" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>If replacing clonidine by beta-blocker therapy, delay the introduction of beta-blockers for several days after clonidine administration has stopped.</SentenceText>
<Mention id="M82" type="Trigger" span="48 5;105 5;136 11" str="delay | after | has stopped"/>
<Mention id="M83" type="Precipitant" span="13 9" str="clonidine" code="MN3L5RMN02"/>
<Interaction id="I28" type="Unspecified interaction" trigger="M82" precipitant="M83"/>
</Sentence>
<Sentence id="5425" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>When administered concurrently the following drugs may interact with thiazide diuretics: Alcohol, barbiturates, or narcotics – Potentiation of orthostatic hypotension may occur.</SentenceText>
<Mention id="M90" type="Trigger" span="127 12" str="Potentiation"/>
<Mention id="M85" type="Precipitant" span="89 7" str="Alcohol" code="3K9958V90M"/>
<Mention id="M92" type="SpecificInteraction" span="143 23" str="orthostatic hypotension" code="28651003: Orthostatic hypotension (disorder)"/>
<Mention id="M88" type="Precipitant" span="98 12" str="barbiturates" code="N0000175693"/>
<Mention id="M91" type="Precipitant" span="115 9" str="narcotics" code="NO MAP"/>
<Interaction id="I29" type="Pharmacodynamic interaction" trigger="M90" precipitant="M85" effect="M92"/>
<Interaction id="I30" type="Pharmacodynamic interaction" trigger="M90" precipitant="M88" effect="M92"/>
<Interaction id="I31" type="Pharmacodynamic interaction" trigger="M90" precipitant="M91" effect="M92"/>
</Sentence>
<Sentence id="5426" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Antidiabetic drugs (oral agents and insulin) – Dosage adjustment of the antidiabetic drug may be required.</SentenceText>
<Mention id="M97" type="Trigger" span="47 17" str="Dosage adjustment"/>
<Mention id="M94" type="Precipitant" span="0 12;20 11" str="Antidiabetic | oral agents" code="NO MAP"/>
<Mention id="M96" type="Precipitant" span="72 17" str="antidiabetic drug" code="NO MAP"/>
<Mention id="M98" type="Precipitant" span="36 7" str="insulin" code="N0000175944"/>
<Interaction id="I32" type="Unspecified interaction" trigger="M97" precipitant="M94"/>
<Interaction id="I33" type="Unspecified interaction" trigger="M97" precipitant="M96"/>
<Interaction id="I34" type="Unspecified interaction" trigger="M97" precipitant="M98"/>
</Sentence>
<Sentence id="5427" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Other antihypertensive drugs – Additive effect or potentiation.</SentenceText>
<Mention id="M99" type="Trigger" span="50 12" str="potentiation"/>
<Mention id="M103" type="Precipitant" span="6 22" str="antihypertensive drugs" code="N0000178477"/>
<Mention id="M101" type="SpecificInteraction" span="6 16;50 12" str="antihypertensive | potentiation" code="NO MAP"/>
<Mention id="M102" type="Trigger" span="31 15" str="Additive effect"/>
<Mention id="M104" type="SpecificInteraction" span="6 16;31 15" str="antihypertensive | Additive effect" code="NO MAP"/>
<Interaction id="I35" type="Pharmacodynamic interaction" trigger="M99" precipitant="M103" effect="M101"/>
<Interaction id="I36" type="Pharmacodynamic interaction" trigger="M102" precipitant="M103" effect="M104"/>
</Sentence>
<Sentence id="5428" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Cholestyramine and colestipol resins – Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.</SentenceText>
<Mention id="M109" type="Trigger" span="39 10;76 8" str="Absorption | impaired"/>
<Mention id="M106" type="Precipitant" span="104 23" str="anionic exchange resins" code="NO MAP"/>
<Mention id="M108" type="Precipitant" span="0 14" str="Cholestyramine" code="4B33BGI082"/>
<Mention id="M110" type="Precipitant" span="19 17" str="colestipol resins" code="K50N755924"/>
<Interaction id="I37" type="Pharmacokinetic interaction" trigger="M109" precipitant="M106" effect="C54356"/>
<Interaction id="I38" type="Pharmacokinetic interaction" trigger="M109" precipitant="M108" effect="C54356"/>
<Interaction id="I39" type="Pharmacokinetic interaction" trigger="M109" precipitant="M110" effect="C54356"/>
</Sentence>
<Sentence id="5429" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.</SentenceText>
<Mention id="M113" type="Trigger" span="92 21" str="reduce its absorption"/>
<Mention id="M112" type="Precipitant" span="23 14" str="cholestyramine" code="4B33BGI082"/>
<Mention id="M114" type="Precipitant" span="41 17" str="colestipol resins" code="K50N755924"/>
<Interaction id="I40" type="Pharmacokinetic interaction" trigger="M113" precipitant="M112" effect="C54356"/>
<Interaction id="I41" type="Pharmacokinetic interaction" trigger="M113" precipitant="M114" effect="C54356"/>
</Sentence>
<Sentence id="5430" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Corticosteroids, ACTH – Intensified electrolyte depletion, particularly hypokalemia.</SentenceText>
<Mention id="M124" type="Trigger" span="24 11" str="Intensified"/>
<Mention id="M119" type="Precipitant" span="17 4" str="ACTH" code="K0U68Q2TXA"/>
<Mention id="M126" type="SpecificInteraction" span="72 11" str="hypokalemia" code="43339004: Hypokalemia (disorder)"/>
<Mention id="M123" type="SpecificInteraction" span="36 21" str="electrolyte depletion" code="166686006: Electrolytes abnormal (finding)"/>
<Mention id="M125" type="Precipitant" span="0 15" str="Corticosteroids" code="N0000175576"/>
<Interaction id="I42" type="Pharmacodynamic interaction" trigger="M124" precipitant="M119" effect="M126"/>
<Interaction id="I43" type="Pharmacodynamic interaction" trigger="M124" precipitant="M119" effect="M123"/>
<Interaction id="I44" type="Pharmacodynamic interaction" trigger="M124" precipitant="M125" effect="M123"/>
<Interaction id="I45" type="Pharmacodynamic interaction" trigger="M124" precipitant="M125" effect="M126"/>
</Sentence>
<Sentence id="5431" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Pressor amines (eg, norepinephrine) – Possible decreased response to pressor amines but not sufficient to preclude their use.</SentenceText>
<Mention id="M130" type="Trigger" span="47 18" str="decreased response"/>
<Mention id="M128" type="Precipitant" span="20 14" str="norepinephrine" code="X4W3ENH1CV"/>
<Mention id="M132" type="SpecificInteraction" span="47 36" str="decreased response to pressor amines" code="NO MAP"/>
<Mention id="M131" type="Precipitant" span="69 14" str="pressor amines" code="NO MAP"/>
<Interaction id="I46" type="Pharmacodynamic interaction" trigger="M130" precipitant="M128" effect="M132"/>
<Interaction id="I47" type="Pharmacodynamic interaction" trigger="M130" precipitant="M131" effect="M132"/>
</Sentence>
<Sentence id="5432" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Skeletal muscle relaxants, nondepolarizing (eg, tubocurarine) – Possible increased responsiveness to the muscle relaxant.</SentenceText>
<Mention id="M139" type="Trigger" span="73 24" str="increased responsiveness"/>
<Mention id="M134" type="Precipitant" span="9 15" str="muscle relaxant" code="N0000175737"/>
<Mention id="M141" type="SpecificInteraction" span="73 47" str="increased responsiveness to the muscle relaxant" code="NO MAP"/>
<Mention id="M137" type="Precipitant" span="0 42" str="Skeletal muscle relaxants, nondepolarizing" code="N0000175738"/>
<Mention id="M140" type="Precipitant" span="48 12" str="tubocurarine" code="W9YXS298BM"/>
<Interaction id="I48" type="Pharmacodynamic interaction" trigger="M139" precipitant="M134" effect="M141"/>
<Interaction id="I49" type="Pharmacodynamic interaction" trigger="M139" precipitant="M137" effect="M141"/>
<Interaction id="I50" type="Pharmacodynamic interaction" trigger="M139" precipitant="M140" effect="M141"/>
</Sentence>
<Sentence id="5433" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Lithium – Generally should not be given with diuretics.</SentenceText>
<Mention id="M142" type="Trigger" span="20 19" str="should not be given"/>
<Mention id="M143" type="Precipitant" span="0 7" str="Lithium" code="9FN79X2M3F"/>
<Interaction id="I51" type="Unspecified interaction" trigger="M142" precipitant="M143"/>
</Sentence>
<Sentence id="5434" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.</SentenceText>
<Mention id="M144" type="Trigger" span="16 26" str="reduce the renal clearance "/>
<Mention id="M145" type="Trigger" span="85 8" str=" toxicity"/>
<Mention id="M146" type="Precipitant" span="46 7" str="lithium" code="9FN79X2M3F"/>
<Interaction id="I52" type="Pharmacokinetic interaction" trigger="M144;M145" precipitant="M146" effect="C54357"/>
</Sentence>
<Sentence id="5435" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Refer to the package insert for lithium preparations before use of such preparations with DUTOPROL.</SentenceText>
<Mention id="M147" type="Trigger" span="0 27" str="Refer to the package insert"/>
<Mention id="M148" type="Precipitant" span="32 20" str="lithium preparations" code="9FN79X2M3F"/>
<Interaction id="I53" type="Unspecified interaction" trigger="M147" precipitant="M148"/>
</Sentence>
<Sentence id="5436" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Non-steroidal Anti-inflammatory Drugs – In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing and thiazide diuretics.</SentenceText>
<Mention id="M164" type="Trigger" span="124 6;179 7" str="reduce | effects"/>
<Mention id="M156" type="Precipitant" span="82 37" str="non-steroidal anti-inflammatory agent" code="N0000175722"/>
<Mention id="M160" type="SpecificInteraction" span="124 6;145 11;179 7" str="reduce | natriuretic | effects" code="NO MAP"/>
<Mention id="M166" type="SpecificInteraction" span="124 19;179 7" str="reduce the diuretic | effects" code="NO MAP"/>
<Mention id="M163" type="SpecificInteraction" span="124 6;162 24" str="reduce | antihypertensive effects" code="NO MAP"/>
<Mention id="M165" type="Precipitant" span="0 37" str="Non-steroidal Anti-inflammatory Drugs" code="N0000175722"/>
<Interaction id="I54" type="Pharmacodynamic interaction" trigger="M164" precipitant="M156" effect="M160"/>
<Interaction id="I55" type="Pharmacodynamic interaction" trigger="M164" precipitant="M156" effect="M166"/>
<Interaction id="I56" type="Pharmacodynamic interaction" trigger="M164" precipitant="M156" effect="M163"/>
<Interaction id="I57" type="Pharmacodynamic interaction" trigger="M164" precipitant="M165" effect="M160"/>
<Interaction id="I58" type="Pharmacodynamic interaction" trigger="M164" precipitant="M165" effect="M163"/>
<Interaction id="I59" type="Pharmacodynamic interaction" trigger="M164" precipitant="M165" effect="M166"/>
</Sentence>
<Sentence id="5437" LabelDrug="Dutoprol" section="34073-7">
<SentenceText>Therefore, when DUTOPROL and non-steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</SentenceText>
<Mention id="M167" type="Trigger" span="105 26" str="should be observed closely"/>
<Mention id="M168" type="Precipitant" span="29 39" str="non-steroidal anti- inflammatory agents" code="N0000175722"/>
<Mention id="M169" type="SpecificInteraction" span="160 22" str="effect of the diuretic" code="NO MAP"/>
<Interaction id="I60" type="Pharmacodynamic interaction" trigger="M167" precipitant="M168" effect="M169"/>
</Sentence>
<Sentence id="5438" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Bronchospastic Disease: PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS.</SentenceText>
</Sentence>
<Sentence id="5439" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Because of its relative beta1 cardio-selectivity, however, metoprolol succinate extended release/hydrochlorothiazide may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment.</SentenceText>
</Sentence>
<Sentence id="5440" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Because beta1-selectivity is not absolute, use the lowest possible dose of DUTOPROL.</SentenceText>
</Sentence>
<Sentence id="5441" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Bronchodilators, including beta2—agonists, should be readily available or administered concomitantly.</SentenceText>
</Sentence>
<Sentence id="5442" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Pheochromocytoma: If DUTOPROL is used in the setting of pheochromocytoma, it should be given in combination with an alpha blocker, and only after the alpha blocker has been initiated.</SentenceText>
</Sentence>
<Sentence id="5443" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.</SentenceText>
</Sentence>
<Sentence id="5444" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Major Surgery: Avoid initiation of high-dose regimen of extended— release metoprolol in patients undergoing non-cardiac surgery, since such use in patients with cardiovascular risk factors has been associated with bradycardia, hypotension, stroke and death.</SentenceText>
</Sentence>
<Sentence id="5445" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery, however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.</SentenceText>
<Mention id="M170" type="Trigger" span="192 17" str="augment the risks"/>
<Mention id="M171" type="Precipitant" span="213 18" str="general anesthesia" code="N0000175681"/>
<Mention id="M172" type="SpecificInteraction" span="192 39" str="augment the risks of general anesthesia" code="736523005: At risk of complication of anesthesia (finding)"/>
<Interaction id="I61" type="Pharmacodynamic interaction" trigger="M170" precipitant="M171" effect="M172"/>
</Sentence>
<Sentence id="5446" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Diabetes and Hypoglycemia: Beta-blockers may mask tachycardia occurring with hypoglycemia, but other manifestations such as dizziness and sweating may not be significantly affected.</SentenceText>
</Sentence>
<Sentence id="5447" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Thyrotoxicosis: Beta-adrenergic blockade may mask certain clinical signs of hyperthyroidism, such as tachycardia.</SentenceText>
</Sentence>
<Sentence id="5448" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta—blockade, which might precipitate a thyroid storm.</SentenceText>
</Sentence>
<Sentence id="5449" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Peripheral Vascular Disease: Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.</SentenceText>
</Sentence>
<Sentence id="5450" LabelDrug="Dutoprol" section="34071-1">
<SentenceText>Calcium Channel Blockers: Because of significant inotropic and chronotropic effects in patients treated with beta-blockers and calcium channel blockers of the verapamil and diltiazem type, caution should be exercised in patients treated with these agents concomitantly.</SentenceText>
<Mention id="M179" type="Trigger" span="189 7" str="caution"/>
<Mention id="M174" type="Precipitant" span="127 60" str="calcium channel blockers of the verapamil and diltiazem type" code="N0000175566"/>
<Mention id="M181" type="SpecificInteraction" span="49 34" str="inotropic and chronotropic effects" code="NO MAP"/>
<Mention id="M177" type="Precipitant" span="173 9" str="diltiazem" code="EE92BBP03H"/>
<Mention id="M180" type="Precipitant" span="159 9" str="verapamil" code="CJ0O37KU29"/>
<Interaction id="I62" type="Pharmacodynamic interaction" trigger="M179" precipitant="M174" effect="M181"/>
<Interaction id="I63" type="Pharmacodynamic interaction" trigger="M179" precipitant="M177" effect="M181"/>
<Interaction id="I64" type="Pharmacodynamic interaction" trigger="M179" precipitant="M180" effect="M181"/>
</Sentence>
</Sentences>
<LabelInteractions><LabelInteraction type="Pharmacodynamic interaction" precipitant="catecholamine-depleting drugs" precipitantCode="N0000175640" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="mao | inhibitors" precipitantCode="N0000175744" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="monoamine oxidase (mao) inhibitors" precipitantCode="N0000175744" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="monoamine oxidase | inhibitors" precipitantCode="N0000175744" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="reserpine" precipitantCode="8B1QWR724A" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="catecholamine depletor" precipitantCode="N0000175640" effect="271594007: Syncope (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="catecholamine depletor" precipitantCode="N0000175640" effect="28651003: Orthostatic hypotension (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="catecholamine depletor" precipitantCode="N0000175640" effect="399153001: Vertigo (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="catecholamine depletor" precipitantCode="N0000175640" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="catecholamine depletor" precipitantCode="N0000175640" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="drugs that inhibit cyp2d6" precipitantCode="N0000182135" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="fluoxetine" precipitantCode="01K63SUP8D" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="paroxetine" precipitantCode="41VRH5220H" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="propafenone" precipitantCode="68IQX3T69U" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="quinidine" precipitantCode="ITX08688JL" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="quinidine" precipitantCode="ITX08688JL" effect="C54603"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clonidine" precipitantCode="MN3L5RMN02" effect="233917008: Atrioventricular block (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clonidine" precipitantCode="MN3L5RMN02" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clonidine" precipitantCode="MN3L5RMN02" effect="84094009: Rebound hypertension (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="clonidine" precipitantCode="MN3L5RMN02"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="digitalis glycosides" precipitantCode="F1T8QT9U8B" effect="233917008: Atrioventricular block (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="digitalis glycosides" precipitantCode="F1T8QT9U8B" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diltiazem" precipitantCode="EE92BBP03H" effect="233917008: Atrioventricular block (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diltiazem" precipitantCode="EE92BBP03H" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diltiazem" precipitantCode="EE92BBP03H" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="verapamil" precipitantCode="CJ0O37KU29" effect="233917008: Atrioventricular block (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="verapamil" precipitantCode="CJ0O37KU29" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="verapamil" precipitantCode="CJ0O37KU29" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="alcohol" precipitantCode="3K9958V90M" effect="28651003: Orthostatic hypotension (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="barbiturates" precipitantCode="N0000175693" effect="28651003: Orthostatic hypotension (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="narcotics" precipitantCode="NO MAP" effect="28651003: Orthostatic hypotension (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="antidiabetic | oral agents" precipitantCode="NO MAP"/>
<LabelInteraction type="Unspecified interaction" precipitant="antidiabetic drug" precipitantCode="NO MAP"/>
<LabelInteraction type="Unspecified interaction" precipitant="insulin" precipitantCode="N0000175944"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="antihypertensive drugs" precipitantCode="N0000178477" effect="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="anionic exchange resins" precipitantCode="NO MAP" effect="C54356"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cholestyramine" precipitantCode="4B33BGI082" effect="C54356"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="colestipol resins" precipitantCode="K50N755924" effect="C54356"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="acth" precipitantCode="K0U68Q2TXA" effect="166686006: Electrolytes abnormal (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="acth" precipitantCode="K0U68Q2TXA" effect="43339004: Hypokalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="corticosteroids" precipitantCode="N0000175576" effect="166686006: Electrolytes abnormal (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="corticosteroids" precipitantCode="N0000175576" effect="43339004: Hypokalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="norepinephrine" precipitantCode="X4W3ENH1CV" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="pressor amines" precipitantCode="NO MAP" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="muscle relaxant" precipitantCode="N0000175737" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="skeletal muscle relaxants, nondepolarizing" precipitantCode="N0000175738" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="tubocurarine" precipitantCode="W9YXS298BM" effect="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="lithium" precipitantCode="9FN79X2M3F" effect="C54357"/>
<LabelInteraction type="Unspecified interaction" precipitant="lithium" precipitantCode="9FN79X2M3F"/>
<LabelInteraction type="Unspecified interaction" precipitant="lithium preparations" precipitantCode="9FN79X2M3F"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="non-steroidal anti-inflammatory agent" precipitantCode="N0000175722" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="non-steroidal anti-inflammatory drugs" precipitantCode="N0000175722" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="non-steroidal anti- inflammatory agents" precipitantCode="N0000175722" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="general anesthesia" precipitantCode="N0000175681" effect="736523005: At risk of complication of anesthesia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="calcium channel blockers of the verapamil and diltiazem type" precipitantCode="N0000175566" effect="NO MAP"/>

</LabelInteractions></Label>